Furthermore, the phase 1b CAMILLA study of cabozantinib plus durvalumab in patients with various gastrointestinal malignancies including 10 patients with advanced GC/GEJ also reported that patients with PD-L1 levels in tumours by CPS >5% vs overall population had improved objective response rate, disease control rate, median progression-free survival, and median overall survival.31 The gene discussed is CD274; the disease is gastric cancer.